Recently, Ariyasu et al.5 evaluated the ratio of T790M to EGFR-activating mutations in cytological samples from 33 patients with NSCLC receiving osimertinib using droplet digital polymerase chain reaction (PCR) and found a significant correlation between the T790M ratio and the tumor reduction rate. This evidence concerns the gene EGFR and neoplasm.